OA And RA Flashcards
Rheumatoid Arthritis
-Chronic, systemic autoimmune disease
-Women are 2-3 times more likely to have RA
-Cause is unknown
RA ; CM
Joints
-Articular involvement manifested by pain, stiffness, limitation of movement, signs of inflammation
-As disease progresses, leads to deformity disability
RA; Collaborative care
-A comprehensive program of education and drug therapy
-Physiotherapy
-Occupational therapy
-Long-term relationship with an arthritis health care team
-Balanced nutrition
Joints;
CM
-Onset insidious
-Non-specific fatigue, anorexia, weight-loss and stiffness
-Limited motion
-Pain
Extra-Articular manifestations
-Rheumatoid nodules-25% of patients
-Sjorgens nodule, 10-15% of patients
-Decreased lacrimal and salivary secretion
-Feltys syndrome-inflammatory eye diseases, blood dyscrasias
Nursing interventions focus on
-Pain management
-Exercise therapy; joint mobility
-Self care assistance
Diagnostics
-History and physical
-RF found in 80%
-ESR elevated
-C-reactive protons elevated
-Synovial fluid analysis
-X-ray non conclusive in early stages
Pharmacological therapy RA
-Non-biologic DMARDs
-Biologic DMARDs
-NSAIDs
-Steroids
-Analgesics (Tylenol, Tramacet)
-Hyaluronic acid injections IA
Disease-modifying antirheumatic drugs (DMARDs)
-Modify the disease of RA
-Exhibit anti-inflammatory, antiarthritc, and immunomodulating effects
-Inhibit the movement of various cells into an inflamed, damage area, such as a joint
-Slow onset of action of several weeks versus minutes to hours for NSAIDs
Nonbiological disease-modifying antirheumatic drugs
-Methotrexate
-Leflunomide
-Hydroxychloroquine sulphate
-Sodium aurothiomalate
-Cyclosporine
-Azathioprine
-Sulfasalazine
Biological disease-modifying anti-rheumatic drugs
-Humira
-Tofacitinib
-Anakinra
-Certolizumba
-Etanercept
-Golimumab
-Infliximab
-Adalimumab
-abatacept
-Rituzab
-Tocilizumab
Etanercept (enbrel)
-used to treat rheumatoid arthritis (including juvenile RA) and moderate severe chronic plaque psoriasis
-Patients must be screened for latex allergy (some dosage forms may contain latex)
-Onset of action: 1-2 weeks
-Contraindicated in presence of active infections
-Reactivation of hepatitis and TB has been reported
Nursing implications DMARDs
-Asses for contraindications
-Baseline bloodwork
-Monitor therapeutic responses
-Observe for and monitor adverse effects
Patient teaching key points
-Maintaining neutral joint position
-Use strongest joint available for tasks
-Distribute weight over multiple joints
-Change positions frequently
-Avoid repetitious movement
-Avoid heavy lifting
-sit vs standing for long periods
Osteoarthritis (OA)
-Most common form of joint disease in North America
-Slowly progressive noninflammatory disorder of the synovial joints
-3 million Canadians affected
-Also called degenerative joint disease